TY - JOUR
T1 - European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
AU - Frisoni, Giovanni B.
AU - Festari, Cristina
AU - Massa, Federico
AU - Cotta Ramusino, Matteo
AU - Orini, Stefania
AU - Aarsland, Dag
AU - Agosta, Federica
AU - Babiloni, Claudio
AU - Borroni, Barbara
AU - Cappa, Stefano F.
AU - Frederiksen, Kristian S.
AU - Froelich, Lutz
AU - Garibotto, Valentina
AU - Haliassos, Alexander
AU - Jessen, Frank
AU - Kamondi, Anita
AU - Kessels, Roy PC
AU - Morbelli, Silvia D.
AU - O'Brien, John T.
AU - Otto, Markus
AU - Perret-Liaudet, Armand
AU - Pizzini, Francesca B.
AU - Vandenbulcke, Mathieu
AU - Vanninen, Ritva
AU - Verhey, Frans
AU - Vernooij, Meike W.
AU - Yousry, Tarek
AU - Boada Rovira, Mercè
AU - Dubois, Bruno
AU - Georges, Jean
AU - Hansson, Oskar
AU - Ritchie, Craig W.
AU - Scheltens, Philip
AU - van der Flier, Wiesje M.
AU - Nobili, Flavio
N1 - Funding Information:
LF and FJ were delegated from the European Alzheimer Disease Consortium; FV and MV from the European Association of Geriatric Psychiatry; KSF and FA from the European Academy of Neurology; SDM and VG from the European Association of Nuclear Medicine; DA and JTO from the European DLB Consortium; CB and AK from the Europe, Middle East, and Africa Chapter of the International Federation of Clinical Neurophysiology; TY and MWV from the European Society of Neuroradiology; SFC and RPCK from the Federation of the European Societies of Neuropsychology; BB and MO from the European FTD network; AH and AP-L from the International Federation of Clinical Chemistry; FBP and RV from the European Union of Medical Specialists. We acknowledge unrestricted grants from F Hoffmann-La Roche, Biogen International, Eisai Europe, Life Molecular Imaging, and OM Pharma Suisse. The funders had no role in the conception, design, and implementation of the project nor in data collection, data analysis, interpretation, or discussion of the results. Funders had no privileged access to the project's outputs at any stage.
Funding Information:
LF and FJ were delegated from the European Alzheimer Disease Consortium; FV and MV from the European Association of Geriatric Psychiatry; KSF and FA from the European Academy of Neurology; SDM and VG from the European Association of Nuclear Medicine; DA and JTO from the European DLB Consortium; CB and AK from the Europe, Middle East, and Africa Chapter of the International Federation of Clinical Neurophysiology; TY and MWV from the European Society of Neuroradiology; SFC and RPCK from the Federation of the European Societies of Neuropsychology; BB and MO from the European FTD network; AH and AP-L from the International Federation of Clinical Chemistry; FBP and RV from the European Union of Medical Specialists. We acknowledge unrestricted grants from F Hoffmann-La Roche, Biogen International, Eisai Europe, Life Molecular Imaging, and OM Pharma Suisse. The funders had no role in the conception, design, and implementation of the project nor in data collection, data analysis, interpretation, or discussion of the results. Funders had no privileged access to the project's outputs at any stage.
Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024/3/1
Y1 - 2024/3/1
N2 - The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.
AB - The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.
KW - ALZHEIMERS-DISEASE
KW - COGNITIVE IMPAIRMENT
KW - DEMENTIA
KW - MANAGEMENT
KW - CRITERIA
KW - GUIDELINES
KW - CLASSIFICATION
KW - VARIANT
KW - EEG
U2 - 10.1016/S1474-4422(23)00447-7
DO - 10.1016/S1474-4422(23)00447-7
M3 - Article
SN - 1474-4422
VL - 23
SP - 302
EP - 312
JO - Lancet Neurology
JF - Lancet Neurology
IS - 3
ER -